OB/GYN revises suggested age for cervical ca screening

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 12
Volume 18
Issue 12

The American College of Obstetricians and Gynecologists has recommended that women begin cervical cancer screening at age 21 rather than three years after the onset of sexual activity, as was previously recommended by the group.

The American College of Obstetricians and Gynecologists has recommended that women begin cervical cancer screening at age 21 rather than three years after the onset of sexual activity, as was previously recommended by the group.

ACOG has also modified its recommendations for how often women should be screened for cervical cancer, bringing them more in line with 2002 guidelines put out by the American Cancer Society, according to Debbie Saslow, PhD, director of breast and gynecologic cancer for the American Cancer Society. Cervical cancer affected 11,270 U.S. women in 2009, according to the ACS statistics.

Over the last 30 years, screening has decreased the cervical cancer incidence rate by half, according to ACOG. But screening prior to age 21 often leads to unnecessary follow-up treatment and emotional anxiety for young women who are actually at a very low risk for the disease.

Recent Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content